MediWound Ltd.

MDWD Healthcare Biotechnology

MediWound Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.0 million, down 16.1% from fiscal 2024. In the quarter to June 2026, revenue fell 45.8%, EPS grew 53.7%, free cash flow fell 49.9% and total debt rose 51.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

11.85 0.36 −2.95%
Market cap
$157.6M
P/E
0.0×
Fwd P/E
−6.1×
Dividend yield
—
F-score
5/9
Altman Z
−1.05
Beneish M
−3.69
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

5 5 4 3
ROE
0.00% (63.49%) 0.00% (75.42%)
ROA
(24.36%) (29.90%) (35.04%) (29.06%)
ROIC
0.00% 0.00% 0.00% (6,551.77%)
Return on Tangible Assets
(34.34%) (45.14%) (51.40%) (44.09%)
Average Days of Receivables
105.29 58.78 69.27 107.47
Free Cash Flow per Share
(1.69) (1.90) (1.95) (2.21)
Free Cash Flow
(18.60) (21.63) (25.13) (28.53)
Other line items

Show all line items

Columns are period end dates